Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akriti Seth

Senior Reporter

London, UK
As a correspondent for Channel NewsAsia, Singapore and for India Technology News, Akriti has covered a wide range of subject-matter including politics, economics and technology for a B2B audience. She has also gained experience working for Bloomberg TV India and Mid-Day Mumbai. Akriti is a graduate of the University of Mumbai and holds a masters from Mumbai's Xavier Institute of Communications. Most recently she has worked as a freelance journalist in London, where she is now based, having lived there for the past two years. She enjoys photography and blogging.

Latest From Akriti Seth

ACA Attack Risks Biosimilars Pathway In US

The AAM has filed an amicus brief with the US Supreme Court in an attempt to ensure that the BPCIA biosimilars pathway remains undisturbed by the Court’s decision on the constitutionality of the ACA, also known as Obamacare.

Legislation Legal Issues

Biocon’s Bengaluru Biosimilars Plant Cleared For EU

Biocon is actively expanding its biosimilars manufacturing capacity with an aim to further penetrate EU markets after receiving a GMP approval for a key manufacturing site. The company has ramped up production for trastuzumab and pegfilgrastim, while awaiting approval for bevacizumab.

Manufacturing Biosimilars

Amneal ‘Hyper Focused’ On New Launches

Aiming to “aggressively expand sales,” Amneal has announced that it will be launching 15 new generics by August 2021. Amneal’s generics business has also reported growth beyond its set targets for the first quarter of 2020.

Strategy Generic Drugs

Towa Expects To Grow By Over A Third With Pensa

Towa says it expects consolidating the Pensa business it acquired earlier this year to boost its sales by more than a third in its current financial year. Meanwhile, the Japanese firm has reported sales ahead by 5% in the year ended March 2020 on the back of new launches, as well as growth in profits despite local price cuts.

Sales & Earnings Deals

Endo’s Generics Add $30m Due To COVID-19 Impact

Despite reporting 14% growth in the first quarter of 2020, Endo has forecast a downturn in the second quarter and has withdrawn its full-year financial guidance due to uncertainty regarding the continued impact of the coronavirus pandemic.

Strategy Sales & Earnings

Alvotech Announces Two Successful Adalimumab Studies

Alvotech’s AVT02 proposed adalimumab biosimilar has seen positive results from two clinical trials. The high concentration dosage form of AVT02 differentes it from most of its biosimilar competitors.

Biosimilars Clinical Trials
See All
UsernamePublicRestriction

Register